DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,122 filers reported holding DANAHER CORPORATION in Q2 2024. The put-call ratio across all filers is 1.04 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $666,963 | +0.1% | 2,669 | +0.0% | 0.18% | -3.2% |
| Q1 2024 | $666,331 | +8.0% | 2,668 | +0.0% | 0.19% | -1.1% |
| Q4 2023 | $617,032 | -6.7% | 2,667 | +0.0% | 0.19% | -14.0% |
| Q3 2023 | $661,362 | +4.2% | 2,666 | +0.8% | 0.22% | +7.3% |
| Q2 2023 | $634,949 | -4.7% | 2,646 | +0.1% | 0.21% | -5.5% |
| Q1 2023 | $666,493 | -5.0% | 2,644 | +0.0% | 0.22% | -12.8% |
| Q4 2022 | $701,611 | +2.9% | 2,643 | +0.0% | 0.25% | +1.2% |
| Q3 2022 | $682,000 | +1.8% | 2,642 | +0.0% | 0.25% | +8.3% |
| Q2 2022 | $670,000 | -14.3% | 2,641 | -0.9% | 0.23% | 0.0% |
| Q1 2022 | $782,000 | -10.8% | 2,665 | 0.0% | 0.23% | -9.5% |
| Q4 2021 | $877,000 | +129.0% | 2,665 | +111.8% | 0.25% | +27.9% |
| Q3 2021 | $383,000 | -51.1% | 1,258 | -56.9% | 0.20% | -19.3% |
| Q2 2021 | $783,000 | +19.4% | 2,917 | +0.0% | 0.24% | +11.9% |
| Q1 2021 | $656,000 | +135.1% | 2,916 | +131.8% | 0.22% | -82.6% |
| Q4 2020 | $279,000 | +3.0% | 1,258 | 0.0% | 1.25% | +1.1% |
| Q3 2020 | $271,000 | +22.1% | 1,258 | 0.0% | 1.24% | -0.2% |
| Q2 2020 | $222,000 | – | 1,258 | – | 1.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
| Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
| Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
| Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
| ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
| CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
| Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
| Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
| BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
| Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |